Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/17156
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHockings, Colin-
dc.contributor.authorAlsop, Amber E-
dc.contributor.authorFennell, Stephanie C-
dc.contributor.authorLee, Erinna F-
dc.contributor.authorFairlie, W Douglas-
dc.contributor.authorDewson, Grant-
dc.contributor.authorKluck, Ruth M-
dc.date2018-02-19-
dc.date.accessioned2018-02-22T01:09:09Z-
dc.date.available2018-02-22T01:09:09Z-
dc.date.issued2018-
dc.identifier.citationCell death and differentiation 2018; 25(4): 721-734-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/17156-
dc.description.abstractThe prosurvival Bcl-2 family proteins Mcl-1 and Bcl-xLinhibit apoptosis by sequestering BH3-only proteins such as Bid and Bim (MODE 1) or the effector proteins Bak and Bax (MODE 2). To better understand the contributions of MODE 1 and MODE 2 in blocking cell death, and thus how to bypass resistance to cell death, we examined prescribed mixtures of Bcl-2 family proteins. In a Bim and Bak mixture, Bcl-xLand Mcl-1 each sequestered not only Bim but also Bak as it became activated by Bim. In contrast, in a Bid and Bak mixture, Bcl-xLpreferentially sequestered Bid while Mcl-1 preferentially sequestered Bak. Notably, Bcl-xLcould sequester Bak in response to the BH3 mimetic ABT-737, despite this molecule targeting Bcl-xL. These findings highlight the importance of Bak sequestration in resistance to anti-cancer treatments, including BH3 mimetics.-
dc.language.isoeng-
dc.titleMcl-1 and Bcl-xLsequestration of Bak confers differential resistance to BH3-only proteins.-
dc.typeJournal Article-
dc.identifier.journaltitleCell death and differentiation-
dc.identifier.affiliationThe Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australiaen
dc.identifier.affiliationDepartment of Medical Biology, The University of Melbourne, Parkville, VIC, 3010, Australia-
dc.identifier.affiliationDepartment of Chemical Engineering and Biotechnology, Cambridge, CB3 0AS, UK-
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia-
dc.identifier.affiliationSchool of Cancer Medicine, La Trobe University, Melbourne, VIC, 3086, Australia-
dc.identifier.affiliationDepartment of Biochemistry and Genetics, La Trobe Institute for Molecular Science, Melbourne, VIC, 3086, Australia-
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/29459767-
dc.identifier.doi10.1038/s41418-017-0010-6-
dc.identifier.orcid0000-0001-7894-7294-
dc.identifier.orcid0000-0002-7101-1925-
dc.identifier.pubmedid29459767-
dc.type.austinJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.cerifentitytypePublications-
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.languageiso639-1en-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

18
checked on Jan 9, 2025

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.